On September 29, Gelonghui reported that Chengda Pharmaceutical (301201.SZ) stated during a specific research session that the current sales price of the company's L-carnitine products is relatively stable, showing a slight improvement compared to the lowest market price. There is still some uncertainty about the future price trends of related products.
诚达药业(301201.SZ)：目前公司左旋肉碱产品销售价格相对稳定，较最低行情已略有好转
Chengda Pharmaceuticals (301201.SZ): At present, the sales price of the company's L-carnitine products is relatively stable, slightly improved compared to the lowest market conditions.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated